Header Logo

Connection

Debra Richardson to CD40 Antigens

Back to Details
This is a "connection" page, showing publications Debra Richardson has written about CD40 Antigens.
Debra Richardson
Connection Strength
0.243
CD40 Antigens
  1. First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer. J Immunother Cancer. 2025 Jan 11; 13(1).
    View in: PubMed
    Score: 0.243
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.